RCS - Physiomics PLC - IMC Presentation on Board Changes

PhysiomicsAnnouncement

23/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240123:nRSW5000Aa&default-theme=true

RNS Number : 5000A  Physiomics PLC  23 January 2024

23 January 2024

 

Physiomics plc

("Physiomics" or "the Company")

 

IMC Presentation on Board Changes

 

Physiomics plc (AIM: PYC), the oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions, will provide a brief update on the Board changes via
Investor Meet Company on 29 January 2024 at 1:00 pm GMT. During this
presentation, Jim Millen CEO and Peter Sargent would be happy to take
questions relating to the changes announced yesterday.

The presentation is open to all existing and potential shareholders. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9:00 am GMT the working day before the meeting or at any time during the live
presentation.

Investors can sign up to Investor Meet Company for free and add to meet
Physiomics plc via:
https://www.investormeetcompany.com/physiomics-plc/register-investor
(https://www.investormeetcompany.com/physiomics-plc/register-investor) .
Investors who already follow the Company on the Investor Meet Company platform
will automatically be invited.

 

 

Enquiries:

 

Physiomics plc

Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980

 

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980

 

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 100 projects, involving over 50 targets and 75 drugs, and
has worked with clients such as Merck KGaA, Astellas, Merck & Co and
Bicycle Therapeutics.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZGZMDZDGDZM